Nirmala Gonsalves, MD
Gastroenterology · Chicago, ILNPI 1326038712
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 35.9% of the total. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $1414.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$87K
- Sanofi$71K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- E.r. Squibb & Sons, L.L.C.$22K
- Regeneron$19K
- AstraZeneca$3K
- plus $8K from 6 others
Across 56 payments — averaging $8203.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$147K
- AstraZeneca$126K
- Sanofi$102K
- Bristol Myers Squibb$66K
- E.r. Squibb & Sons, L.L.C.$18K
- Astrazeneca UK Limited$111
What the payments were for
- Consulting fees$109,13245%
- Speaking & faculty fees$101,35742%
- Travel & lodging$28,93412%
- Food & beverage$2,9371%
- Education$9000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 72 | $87,259 |
| Sanofi | 28 | $71,200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $32,171 |
| E.r. Squibb & Sons, L.L.C. | 6 | $22,052 |
| Regeneron | 17 | $19,429 |
| AstraZeneca | 11 | $3,227 |
| Astrazeneca UK Limited | 1 | $3,222 |
| Exact Sciences | 2 | $1,999 |
| AbbVie | 2 | $1,150 |
| Amgen | 1 | $723 |
| Redhill Biopharma Inc. | 1 | $555 |
| Bristol Myers Squibb | 7 | $272 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$243,260 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $80,725 |
| Dexlansoprazole DrDexlansoprazole | 21 | $7,458 |
| Omeprazole | 114 | $2,377 |
| Rabeprazole Sodium | 26 | $2,116 |
| Esomeprazole Magnesium | 30 | $1,319 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 18 | $1,174 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Chicago
- David RubinChicago$1.5M
- Stephen HanauerChicago$1.4M
- Steven FlammChicago$1.3M
- Darren BrennerChicago$1.1M
- Russell CohenChicago$690K
- Parambir DulaiChicago$668K
- Christopher ChapmanChicago$645K
- Saurabh KapurChicago$532K
- Ikuo HiranoChicago$457K
- Adam SteinChicago$438K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.